ATE444081T1 - Proteine-abgabe durch polare epithelzellen schichte - Google Patents

Proteine-abgabe durch polare epithelzellen schichte

Info

Publication number
ATE444081T1
ATE444081T1 AT00975326T AT00975326T ATE444081T1 AT E444081 T1 ATE444081 T1 AT E444081T1 AT 00975326 T AT00975326 T AT 00975326T AT 00975326 T AT00975326 T AT 00975326T AT E444081 T1 ATE444081 T1 AT E444081T1
Authority
AT
Austria
Prior art keywords
bioactive
epithelial cell
cell layer
moiety
polar epithelial
Prior art date
Application number
AT00975326T
Other languages
English (en)
Inventor
David Fitzgerald
Randall Mrsny
Miriam Mckee
Ann Daugherty
Original Assignee
Us Gov Health & Human Serv
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Genentech Inc filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE444081T1 publication Critical patent/ATE444081T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00975326T 1999-10-22 2000-10-18 Proteine-abgabe durch polare epithelzellen schichte ATE444081T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16092399P 1999-10-22 1999-10-22
PCT/US2000/029080 WO2001030392A2 (en) 1999-10-22 2000-10-18 Delivery of proteins across polar epithelial cell layers

Publications (1)

Publication Number Publication Date
ATE444081T1 true ATE444081T1 (de) 2009-10-15

Family

ID=22579051

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00975326T ATE444081T1 (de) 1999-10-22 2000-10-18 Proteine-abgabe durch polare epithelzellen schichte

Country Status (8)

Country Link
US (1) US7824695B1 (de)
EP (1) EP1242122B1 (de)
JP (2) JP2003512441A (de)
AT (1) ATE444081T1 (de)
AU (1) AU784657B2 (de)
CA (1) CA2389302C (de)
DE (1) DE60043070D1 (de)
WO (1) WO2001030392A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2249838T3 (es) * 1997-07-11 2006-04-01 The Government Of The Usa As Represented By The Secretary Of The Depar. Of Health And Human Services Inmunogenos quimericos similares a la exotoxina a de pseudomonas.
CA2389302C (en) * 1999-10-22 2011-03-15 David J. Fitzgerald Delivery of proteins across polar epithelial cell layers
AU2005296064A1 (en) 2004-10-04 2006-04-27 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of macromolecules
US7666991B2 (en) 2005-12-05 2010-02-23 Trinity Biosystems, Inc. Compositions for needleless delivery of antibodies
EP1971367A4 (de) * 2005-12-05 2010-04-07 Trinity Biosystems Inc Verfahren und zusammensetzungen zur nadellosen abgabe von bindungspartnern
CA2647168A1 (en) * 2006-03-16 2007-09-27 Trinity Biosystems, Inc. Methods for increasing the size of animals using needleless delivery constructs
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
SI3762009T1 (sl) 2018-03-08 2023-03-31 Applied Molecular Transport Inc. Iz toksinov izpeljani dostavni konstrukti za peroralno dostavo
AU2019374703A1 (en) 2018-11-07 2021-06-24 Applied Molecular Transport Inc. Cholix-derived carriers for oral delivery of heterologous payload
WO2021034727A1 (en) 2019-08-16 2021-02-25 Applied Molecular Transport Inc. Compositions, formulations, and interleukin production and purification

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78775A (en) * 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
AU4646393A (en) * 1992-06-23 1994-01-24 Interactive Biologics Associates Pharmaceutical composition containing botulinum b complex
WO1995007297A1 (en) 1993-09-06 1995-03-16 Menarini Ricerche Sud S.P.A. Ribosome inactivating proteins extracted from seeds of saponaria ocymoides and vaccaria pyramidata, their preparation and immunotoxins containing them
JPH10500670A (ja) 1994-05-13 1998-01-20 エクラゲン リミテッド ペプチド送達の改良またはペプチド送達との関連
DE69729389D1 (de) * 1996-11-06 2004-07-08 Nasa Protease-aktivierbare pseudomonas exotoxin-a-ähnliche proproteine
US6086900A (en) * 1997-03-26 2000-07-11 Board Of Regents, The University Of Texas Systems Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
ES2249838T3 (es) * 1997-07-11 2006-04-01 The Government Of The Usa As Represented By The Secretary Of The Depar. Of Health And Human Services Inmunogenos quimericos similares a la exotoxina a de pseudomonas.
US20030054012A1 (en) 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
US6472140B1 (en) * 1997-09-05 2002-10-29 The General Hospital Corporation α-2- macroglobulin therapies and drug screening methods for Alzheimer's disease.
CA2389302C (en) * 1999-10-22 2011-03-15 David J. Fitzgerald Delivery of proteins across polar epithelial cell layers
US6881718B1 (en) * 1999-10-22 2005-04-19 The United States Of America As Represented By The Department Of Health And Human Services Disulfide conjugated cell toxins and methods of making and using them
DE60137969D1 (de) 2000-12-21 2009-04-23 Us Gov Health & Human Serv Ein chimäres protein das nichttoxische pseudomonas exotoxin a und typ iv pilin sequenzen enthält

Also Published As

Publication number Publication date
AU784657B2 (en) 2006-05-18
AU1339201A (en) 2001-05-08
WO2001030392A2 (en) 2001-05-03
US7824695B1 (en) 2010-11-02
CA2389302A1 (en) 2001-05-03
WO2001030392A3 (en) 2002-07-11
DE60043070D1 (de) 2009-11-12
JP2012051939A (ja) 2012-03-15
JP2003512441A (ja) 2003-04-02
EP1242122B1 (de) 2009-09-30
EP1242122A2 (de) 2002-09-25
CA2389302C (en) 2011-03-15

Similar Documents

Publication Publication Date Title
PT817847E (pt) Receptor de il-17
CY1118504T1 (el) Τριμερης πρωτεϊνη συντηξης του συνδετη οχ40 στην περιοχη ανοσοσφαιρινης και τροποι χρησης
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
ES2080055T3 (es) Construcciones de antigenos de antigenos del "complejo de histocompatibilidad principal" de la clase i con moleculas de vehiculo especificas, su preparacion y empleo.
ES2141467T3 (es) Anticuerpos anti-cd 30 que impiden la escision proteolitica y liberacion del antigeno cd-30 fijado a la membrana.
ES2099211T3 (es) Conjugados citomoduladores de miembros de parejas de union especifica.
ES2187946T3 (es) Uso de interleucina-15.
DE69834808D1 (de) Multiple,kohlenhydrathaltige glycopeptid-antigene, daraus entwickelte impfstoffe sowie deren verwendung
BRPI0406574A (pt) Conjugados de anticorpo - antraciclina
LU91758I2 (fr) Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)
ATE444081T1 (de) Proteine-abgabe durch polare epithelzellen schichte
NO20041325L (no) Substanser
ES2185705T3 (es) Proteina bifuncional, preparacion y uso.
DK1157042T3 (da) Fremstilling af tetravalente antistoffer
ES2180538T3 (es) Suministro dirigido de vector virico a celulas de mamiferos.
DK0672063T3 (da) Mindste genkendelsesenhed af et PEM mucintandemgentagelsesspecifikt monoklonalt antistof
DE69726674T2 (de) Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren
CY1109710T1 (el) Επιτοπα βοηθητικων τ λεμφοκυτταρων
DE69830492D1 (de) Antikörper als ARZNEIMITTEL GEGEN LYMPHOCYTISCHE TUMORE (AUSSCHLIESSLICH MYELOME)
DK1331944T3 (da) Anvendelse af CD28-specifikke monoklonale antistoffer til stimulering af blodlegemer, der ikke bærer CD28
EP1354896A4 (de) Neuer monoklonaler antikörper
ATE375514T1 (de) Zusammensetzungen und methoden zur detektion einer trypanosoma cruzi infektion
ATE552860T1 (de) Antikörper-vakzine-konjugate und ihre verwendungen
NO972522L (no) Monoklonale antistoffer med immunoundertrykkende aktivitet

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties